HOXC-AS3 promoted tumorigenicity and progression in HCC through modulating CDK2 and p21 to trigger the activation of the Rb/E2F1 pathway, according to mechanistic studies. This evidence concerns the gene E2F1 and hepatocellular carcinoma.